Clinical trial
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory…
NCT00268359 · Duke University, Other · Completed
Key facts
| NCT number | NCT00268359 |
|---|---|
| Title | Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas |
| Official title | Bevacizumab in Combination With Irinotecan for Malignant Gliomas |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, irinotecan hydrochloride |
| Enrollment | 68 |
| Start date | May 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Oct 1, 2009 |
| First posted | Dec 22, 2005 |
| Last update posted | Jul 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: